The study involved patients hospitalised for an acute attack of TS from May 2006 to August 2013 at the Department of Internal Medicine and Cardiology of the University Hospital Brno. A total of 24 patients (23 women, 1 man) were admitted to the coronary acute unit with suspected acute coronary syndrome, and subsequently were diagnosed with TS according to the Mayo Clinic criteria [3 (link)]. ECG changes, hs-troponin T levels (Roche Diagnostics, Indianapolis, IN, USA, with the cut-off value at 14 ng/L), NT-proBNP (Roche Diagnostics, Indianapolis, IN, USA; with the cut-off value at 100 pg/mL), C-reactive protein (Roche, Basel, Switzerland, with the cut-off value at 5 mg/L) (all biomarkers were measured at admission), coronary angiography finding, and left ventricular function (assessed by echocardiography and left ventriculography) were evaluated in all patients. The study involved only patients with a history of TS and a documented recovery of left ventricular function. Some patients were also examined by magnetic resonance imaging (MRI) in order to rule out ischaemic aetiology or acute myocarditis. The control group was composed of 27 healthy volunteers (20 women, 7 men) who had a similar environmental burden with metals according to the questionnaire.
C reactive protein (crp)
Manufactured by Roche
Sourced in Switzerland
C-reactive protein is a laboratory test that measures the level of a specific protein in the blood. This protein is produced by the liver and its levels increase in response to inflammation or infection in the body. The C-reactive protein test can be used to help detect and monitor various medical conditions.
Automatically generated - may contain errors
Lab products found in correlation
10 protocols using c reactive protein (crp)
1
Takotsubo Syndrome Clinical Characteristics
2
Evaluating Glomerular Filtration Rate
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The Glomerular Filtration Rate (GFR) was evaluated through creatinine clearance, utilizing a 24 h urine collection. Creatinine was measured with an enzymatic assay utilizing isotope dilution mass spectrometry standard calibrated method (Roche Diagnostics S.p.A. Monza, Italy). PTH was measured with an immunometric assay in chemiluminescence (Diagnostic Products Corporation, Los Angeles, CA, USA) and C-reactive protein with an immunoturbidimetric high sensitivity assay system (Roche Diagnostics S.p.A. Monza, Italy).
3
Blood Withdrawal and Hematological Measures
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
In each campaign, 596 mL of blood was drawn per subject over the 56 days duration of each campaign. This included 441 mL drawn between BDC5 and HDT21, or 17.6 mL/day at 14.5 g/dL of Hb; venipuncture corresponded to an estimated loss of 2.5 g Hb/day. All blood was drawn in the bedridden position. Assays were performed at MLM Medical (Moenchengladbach, Germany). Hematocrit, hemoglobin, and erythrocyte concentrations were measured using a Counter ABXpentra60Cplus. Reticulocytes were counted manually. Haptoglobin was measured by nephelometric assay (Siemens, Marburg, Germany). Total and direct/conjugated bilirubins were measured using photometric assays, ferritin by electrochemiluminescence assay, C‐reactive protein by immunoturbidimetric assay (Roche, Mannheim, Germany), and EPO by chemiluminescent immunoassay (Beckman, Krefeld, Germany).
4
Comprehensive Cardiometabolic Profiling Protocol
5
Comprehensive Clinical Biomarker Profiling
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
All clinical chemistry parameters including total, LDL and HDL-cholesterol, TAG
(enzymatic photometric assay; Roche Diagnostics), HbA1c, C-reactive protein
(quantitative immunoturbidimetric assay; Roche Diagnostics), glucose (hexokinase assay)
and whole blood count (flow cytometry; Sysmex) were measured from yellow and purple top
serum vacutainer tubes using standard techniques by the Institute for Clinical Chemistry,
University Duesseldorf, Germany.
(enzymatic photometric assay; Roche Diagnostics), HbA1c, C-reactive protein
(quantitative immunoturbidimetric assay; Roche Diagnostics), glucose (hexokinase assay)
and whole blood count (flow cytometry; Sysmex) were measured from yellow and purple top
serum vacutainer tubes using standard techniques by the Institute for Clinical Chemistry,
University Duesseldorf, Germany.
6
Pleural Fluid Biomarker Analysis
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Pleural fluid ADA levels were determined by using an automated ultraviolet kinetic assay (Roche Diagnostics, Barcelona, Spain). Nine biomarkers, which were selected as potentially discriminatory from the derivation sample, were measured either by enzyme-linked immunosorbert assays (human cathepsin-B, human kallikrein-12, human condroitin sulfate, human matrix metalloproteinase 3 [MMP-3], human matrix metalloproteinase 9 [MMP-9], and human angiostatin; Cusabio Biothech), a particle-enhanced immunoturbidimetric assay (C-reactive protein; Roche Diagnostics GmbH, Mannheim, Germany), or electro-chemiluminiscence immunoassays (CA15-3 and CA19-9; Roche Diagnostics GmbH, Mannheim, Germany) in the pleural fluid of an independent population.
7
Comprehensive Assessment of Kidney and Heart Disease
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
These are detailed in the methods paper [17 (link)] but in brief patients underwent assessments at baseline, 1 month and 3 months. These consisted of the 6-min walk test (6MWT), laboratory measurements including eGFR and biochemical profile (BCP), full blood count (FBC), haemoglobin (Hb), serum ferritin (SF), transferrin saturation (TSAT), C-reactive protein (CRP) and NT-ProBNP (Roche diagnostics) and cystatin C. Quantification of proteinuria was carried out by measurement of urinary protein:creatinine ratio (uPCR) or if diabetic, urinary albumin:creatinine ratio (uACR) depending on availability and use in the recruiting centres. New York Association Functional classification (NYHA), electrocardiogram (ECG) and 2D echo were carried out in all Group 1 patients at baseline, 1 and 3 months. Two questionnaires: the Kidney Disease Quality of Life Short Form Questionnaire (KDQoL-SF-36) and The Minnesota Living with Heart Failure Questionnaire (MLHF) were completed at the three time points for Groups 1. Pulse wave velocity (PWV) and augmentation index (AiX) measurements were performed at baseline and at months 1 and 3 for Groups 1.
8
Blood biomarker analysis protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Blood samples were obtained from participants who had fasted for at least 10 hours. These were stored in EDTA anti-coagulant tubes. SUA, TG, HDL, LDL, fasting blood glucose, aspartate transaminase (AST), ALT, homocysteine and CRP were measured in the CDC’s laboratory with a Hitachi (7600) automatic analyzer using Wako Diagnostics reagent, except for CRP (Roche, Basel, Switzerland), in accordance with the instructions of the manufacturer.
9
Immunotherapy Follow-up: Serological and Blood Profile Assessment
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
All serological tests and blood counts were performed during routinely scheduled examinations as recommended for patients during follow-up after immunotherapy. Blood tests were performed in an accredited university hospital laboratory (Institute of Medical Biochemistry and Laboratory Diagnostics, General University hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic). The laboratory complies with national accreditation standards (ČSN, EN ISO 15189; 2013), which guarantee the accuracy of verified results. Normal value range and pathological limits were determined by the producer. S100B (Roche, Switzerland) was performed by Electro-chemiluminescence immunoassay (ECLIA) for the in vitro quantitative determination of S100 in human serum. LDH (Roche, Switzerland) was performed by International Federation of Clinical Chemistry (IFCC) methods, and CRP (Roche) was performed by nephelometry using a Dade Behring BNII instrument. Blood count, neutrophils abs. and lymphocytes abs. were performed by automatic analyzer. The serological markers used, and the examination of the blood count, physiological limits and critical values are summarized in Table 1 .
10
Serological Markers of Rheumatoid Arthritis
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Serum IgM RF and high sensitivity CRP (hsCRP) were assessed by quantitative nephelometry (Cobas Mira Plus, Roche), using RF and CRP reagents, respectively (both Dialab, Vienna, Austria). RF levels > 50 IU/ml indicated seropositivity and hsCRP levels > 5 mg/l were considered elevated. Anti-CCP autoantibodies were detected in serum samples using the second generation Immunoscan-RA CCP2 ELISA test (Euro Diagnostica, Arnhem, The Netherlands).
The assay was performed according to the instructions of the manufacturer. A concentration > 25 IU/ml indicated seropositivity.
We also calculated the mean ESR (mESR), CRP (mCRP) and DAS28 (mDAS28) values based on three monthly assessments within the past 3 years (up to 12 assessments) (Table 1). We applied the EULAR DAS28 remission and low disease activity criteria: DAS28 remission: < 2.6, low disease activity < 3.2.
The assay was performed according to the instructions of the manufacturer. A concentration > 25 IU/ml indicated seropositivity.
We also calculated the mean ESR (mESR), CRP (mCRP) and DAS28 (mDAS28) values based on three monthly assessments within the past 3 years (up to 12 assessments) (Table 1). We applied the EULAR DAS28 remission and low disease activity criteria: DAS28 remission: < 2.6, low disease activity < 3.2.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!